BioCentury
ARTICLE | Company News

AOP Orphan, Cardiome sales and marketing update

July 15, 2013 7:00 AM UTC

Cardiome granted AOP Orphan rights to market atrial fibrillation drug IV Brinavess vernakalant in European countries for three years, with the possibility of extension. The deal includes Austria; Bosnia and Herzegovina; Bulgaria; Croatia; the Czech Republic; Estonia; Hungary; Kazakhstan; Latvia; Lithuania; Montenegro; Macedonia; Poland; Romania; Serbia; Slovakia; Slovenia; Switzerland; and Ukraine. The companies did not disclose financial details.

Brinavess is approved in the EU for rapid conversion of recent onset AF to sinus rhythm for non-surgery, adult patients with AF of at least seven days and for post-cardiac surgery, adult patients with AF of at least three days. ...